head uk2

Publications in September 2011

In September a total of 62 articles were published in the field of chitosan. In this month the most publications came from China where 10 articles were published. With 7 articles India was in second place followed by the USA where 6 articles were published.

Top Journals Publications
J Biomater Sci Polym Ed 5
Tissue Eng Part A 4
Int J Pharm 3
J Colloid Interface Sci 3
J Biomed Mater Bes A 3

Table: Journals with the most publications about chitosan and chitosan derivatives.

Below two articles about chitosan coatings are shortly introduced.

Chitosan-Based Ultrathin Films as Antifouling, Anticoagulant and Antibacterial Protective Coatings

M. Bulwan, K. Wójcik, S. Zapotoczny, M. Nowakowska, J Biomater Sci Polym Ed. 2011, 29.

Using layer by layer deposition methodology the team of Bulwan prepared ultrathin films from ionic derivatives of chitosan with antifouling, anticoagulant and antibacterial properties.

Silicon and glass surfaces protected by these nanocoatings were resistant to non-specific adsorption of proteins. Furthermore microscopic studies (SEM, AFM) and the MTT viability test showed that the formation of bacterial (Staphylococcus aureus) biofilms was prevented by the coatings.

The authors account these chitosan based protective coatings as promising for biomedical applications (for example as protective coatings for medical devices). In this case anticoagulant and antifouling properties are also important. These properties could be shown in the studies of Bulwan et al.

The studies also found the biologically relevant properties to be dependent on the thickness of those nanocoatings.

 Source: National Center for Biotechnology Information

Development and characterization of chitosan coated poly-(ε-caprolacone) nanoparticulate system for effective immunization against influenza

N. K. Gupta, V. Sharma, V. K. Dixit, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University, Sagar, India (Vaccine. 2011 Sep 19.)

For an effective nasal immunization Gupta, Sharma and Dixit developed a carrier system in the form of a poly-(ε-caprolactone) nanoparticles coated with chitosan (CS-PCL). The characterization of the CS-PCL nanoparticles was effected in vitro for their percent yield, size, shape, entrapment efficiency, loading capacity and zeta potential. Also evaluated were the in vitro release and antigen integrity. As antigen they used recombinant Influenza A virus (A/California/07/2009) H1N1 hemagglutinin (HA) protein.

Determined values:

size 125.64 ± 6.51 nm (with narrow size distribution (PDI: 0.185 ± 0.032))
positive surface charge 22.88 mV
entrapment efficiency 74.84 ± 4.51%
loading capacity and zeta potential 14 ± 2% (w/w)
66.47% of entrapped antigen was released within 63 days  

The positive results of a cogent immune response demonstrate high potential of the CS-PCL nanoparticle adjuvant for nasal administered influenza antigen carriers.

Source: National Center for Biotechnology Information

Source: GoPubMed

chitosan, nanoparticles, coating

  • Created on .

Congress and fairs

Meet us in person 2024:

  • 14th PBP World Meeting/ Research Pharm, Vienna, Austria, 18.-21.03.2024
  • CPHI, Milan, Italy, 08.-10.10.2024
  • MEDICA 2024, Düsseldorf, Germany, 11.-14.11.2024

To arrange an appointment please contact Katja Richter via This email address is being protected from spambots. You need JavaScript enabled to view it.


  • Heppe Medical Chitosan GmbH
    Heinrich-Damerow-Strasse 1
    06120 Halle (Saale)
  • Tel.: +49 (0) 345 27 996 300
    Fax: +49 (0) 345 27 996 378
  • This email address is being protected from spambots. You need JavaScript enabled to view it.
Contact | GTC / Terms of Use | Legal info | Copyright © 2024 Heppe Medical Chitosan GmbH | Privacy notice

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.